Journal
BLOOD
Volume 112, Issue 9, Pages 3807-3817Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2008-05-157131
Keywords
-
Categories
Funding
- Leukaemia Research UK
- Leukaemia Research Appeal for Wales
- Welsh Bone Marrow Transplant
Ask authors/readers for more resources
Bcl-2 family proteins play a critical role in the regulation of apoptosis in chronic lymphocytic leukemia (CLL). However, their association with established prognostic markers is unknown. In this study, we analyzed the expression of Bcl-2, Bax, and Mcl-1 in 185 CLL patients and evaluated their relationship with other prognostic markers, in vitro sensitivity to fludarabine, and clinical outcome. Mcl-1 expression was significantly correlated with stage of disease (P <.001), lymphocyte doubling time (P =.01),V-H gene mutation status (P <.001), CD38 expression (P <.001), and ZAP-70 expression (P= .003). In addition, Mcl-1 and Mcl-1/Bax ratios showed strong correlations with in vitro resistance to fludarabine (P =.005 and P <.001, respectively). Furthermore, elevated Mcl-1 expression and Mcl-1/Bax ratios were predictive of time to first treatment in the whole cohort (P <.001 and P <.001, respectively) and in stage A patients only (P =.002 and P =.001, respectively). Taken together, our data show that Mcl-1 is a key controller of in vitro drug resistance and is an important regulator of disease progression and outcome in CLL. It therefore represents a promising therapeutic target in this incurable condition. The close correlation between Mcl-1 expression and VH gene mutation status, CD38 expression, and ZAP-70 expression offers a biologic explanation for their association with adverse prognosis. (Blood. 2008; 112:3807-3817)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available